MCID: HMN036
MIFTS: 55

Hemangiopericytoma, Malignant

Categories: Cancer diseases, Rare diseases

Aliases & Classifications for Hemangiopericytoma, Malignant

MalaCards integrated aliases for Hemangiopericytoma, Malignant:

Name: Hemangiopericytoma, Malignant 57 12 73
Hemangiopericytoma 12 76 53 55 44 15 73
Solitary Fibrous Tumor 59 73
Haemangiopericytic Meningioma 12
Malignant Hemangiopericytoma 12

Characteristics:

Orphanet epidemiological data:

59
solitary fibrous tumor
Inheritance: Not applicable; Age of onset: All ages; Age of death: any age;

OMIM:

57
Inheritance:
autosomal recessive


HPO:

32
hemangiopericytoma, malignant:
Inheritance autosomal recessive inheritance


Classifications:



External Ids:

OMIM 57 234820
Disease Ontology 12 DOID:264
MeSH 44 D006393
NCIt 50 C3087
SNOMED-CT 68 36060005
Orphanet 59 ORPHA2126
UMLS via Orphanet 74 C1266119 C0018922
MESH via Orphanet 45 D006393
ICD10 via Orphanet 34 D21.9
MedGen 42 C0334542
SNOMED-CT via HPO 69 258211005 49601007

Summaries for Hemangiopericytoma, Malignant

NIH Rare Diseases : 53 Hemangiopericytoma is a term used to described a group of tumors that are derived from pericytes, the cells normally arranged along specific types of blood vessels called capillaries and venules. These types of tumors are typically slow-growing, may be either benign (non-cancerous) or malignant (cancerous), and may occur anywhere in the body.

MalaCards based summary : Hemangiopericytoma, Malignant, also known as hemangiopericytoma, is related to meninges hemangiopericytoma and secretory meningioma. An important gene associated with Hemangiopericytoma, Malignant is STAT6 (Signal Transducer And Activator Of Transcription 6), and among its related pathways/superpathways are ERK Signaling and Cytoskeletal Signaling. The drugs Mechlorethamine and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include liver, kidney and brain, and related phenotypes are abnormality of the cardiovascular system and homeostasis/metabolism

Disease Ontology : 12 A soft tissue cancer that is a soft tissue sarcoma and originates in the pericytes in the walls of capillaries.

Wikipedia : 76 A hemangiopericytoma (HPC) is a type of soft tissue sarcoma that originates in the pericytes in the... more...

Description from OMIM: 234820

Related Diseases for Hemangiopericytoma, Malignant

Diseases in the Hemangiopericytoma, Malignant family:

Adult Malignant Hemangiopericytoma

Diseases related to Hemangiopericytoma, Malignant via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 270)
# Related Disease Score Top Affiliating Genes
1 meninges hemangiopericytoma 33.7 IGF2 STAT6 VIM
2 secretory meningioma 30.6 MUC1 VIM
3 meningioma, familial 30.5 IGF2 NAB2 STAT6
4 glomus tumor 30.5 ACTC1 DES VIM
5 hypoglycemic coma 30.4 HBA1 IGF2
6 infantile myofibromatosis 30.4 ACTC1 DES VIM
7 liposarcoma 30.2 DES MDM2 VIM
8 spindle cell lipoma 30.2 ACTC1 DES MDM2 VIM
9 dedifferentiated liposarcoma 30.2 ACTC1 DES MDM2
10 sarcoma, synovial 30.1 DES MDM2 MUC1 VIM
11 endometrial stromal sarcoma 30.1 ACTC1 DES VIM
12 intravascular papillary endothelial hyperplasia 30.1 ACTC1 VIM
13 pseudosarcomatous fibromatosis 30.0 ACTC1 DES VIM
14 adenofibroma 30.0 ACTC1 MUC1 VIM
15 myoepithelioma 29.9 ACTC1 S100B VIM
16 mesenchymal chondrosarcoma 29.9 DES MUC1 VIM
17 fasciitis 29.9 ACTC1 DES MUC1 VIM
18 fibrous meningioma 29.8 F13A1 MUC1 S100B VIM
19 monophasic synovial sarcoma 29.8 MUC1 S100B VIM
20 pleomorphic adenoma 29.8 ACTC1 MDM2 MUC1 S100B VIM
21 leiomyoma 29.8 ACTC1 DES IGF2 VIM
22 neurofibroma 29.7 F13A1 MUC1 S100B
23 fibrous histiocytoma 29.7 ACTC1 DES F13A1 S100B VIM
24 chordoma 29.7 DES MUC1 S100B VIM
25 dermatofibrosarcoma protuberans 29.6 ACTC1 DES F13A1 S100B VIM
26 gastrointestinal stromal tumor 29.5 ACTC1 DES IGF2 S100B VIM
27 neurilemmoma 29.5 DES NGFR S100B VIM
28 spindle cell sarcoma 29.4 ACTC1 DES MDM2 MUC1 S100B VIM
29 malignant pleural solitary fibrous tumor 12.5
30 malignant peritoneal solitary fibrous tumor 12.4
31 breast hemangiopericytoma 12.3
32 kidney hemangiopericytoma 12.2
33 retroperitoneal hemangiopericytoma 12.2
34 conventional malignant hemangiopericytoma 12.0
35 adult malignant hemangiopericytoma 12.0
36 benign fibrous mesothelioma 11.6
37 liver fibroma 11.3
38 desmoid tumor 11.2
39 heart malignant hemangiopericytoma 11.1
40 malignant mediastinum hemangiopericytoma 11.1
41 adult intracranial malignant hemangiopericytoma 11.1
42 childhood malignant hemangiopericytoma 11.1
43 hypoglycemia 10.5
44 potter's syndrome 10.4
45 infantile digital fibromatosis 10.3 DES VIM
46 lymphangiomatosis 10.3 DES VIM
47 osteomalacia 10.3
48 sarcoma 10.3
49 lymphangiectasis 10.3 ACTC1 VIM
50 primitive neuroectodermal tumor of the cervix uteri 10.3 DES VIM

Graphical network of the top 20 diseases related to Hemangiopericytoma, Malignant:



Diseases related to Hemangiopericytoma, Malignant

Symptoms & Phenotypes for Hemangiopericytoma, Malignant

Symptoms via clinical synopsis from OMIM:

57
Vascular:
malignant hemangiopericytoma


Clinical features from OMIM:

234820

Human phenotypes related to Hemangiopericytoma, Malignant:

32
# Description HPO Frequency HPO Source Accession
1 abnormality of the cardiovascular system 32 HP:0001626

MGI Mouse Phenotypes related to Hemangiopericytoma, Malignant:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.11 ACTC1 DES F13A1 FGF23 IGF2 MDM2
2 cardiovascular system MP:0005385 10.06 ACTC1 DES F13A1 FGF23 HACL1 IGF2
3 mortality/aging MP:0010768 9.96 ACTC1 DES F13A1 FGF23 IGF2 MDM2
4 integument MP:0010771 9.87 FGF23 IGF2 MDM2 NAB2 NGFR S100B
5 muscle MP:0005369 9.63 ACTC1 DES IGF2 MDM2 NGFR VIM
6 reproductive system MP:0005389 9.5 F13A1 FGF23 IGF2 MDM2 NAB2 STAT6
7 respiratory system MP:0005388 9.17 F13A1 FGF23 IGF2 NAB2 NGFR STAT6

Drugs & Therapeutics for Hemangiopericytoma, Malignant

Drugs for Hemangiopericytoma, Malignant (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 63)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1 51-75-2 4033
2
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
3
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
4
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
5
Carboplatin Approved Phase 3,Phase 2 41575-94-4 10339178 38904 498142
6
Dactinomycin Approved, Investigational Phase 3,Phase 2 50-76-0 457193 2019
7
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
8
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 6055-19-2, 50-18-0 2907
9
Vincristine Approved, Investigational Phase 3,Phase 2 57-22-7, 2068-78-2 5978
10
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
11
Trabectedin Approved, Investigational Phase 2, Phase 3 114899-77-3 108150
12
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
13
Isophosphamide mustard Phase 3,Phase 2,Phase 1 0
14 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
15 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
16 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
17 Alkylating Agents Phase 3,Phase 2,Phase 1
18 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
19 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
20 Immunologic Factors Phase 3,Phase 2
21 Anti-Infective Agents Phase 3,Phase 2
22 Etoposide phosphate Phase 3,Phase 2
23 Antimitotic Agents Phase 3,Phase 2
24 Antirheumatic Agents Phase 3,Phase 2,Phase 1
25 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
26 Immunosuppressive Agents Phase 3,Phase 2
27
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
28
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
29
Bevacizumab Approved, Investigational Phase 2 216974-75-3
30
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
31
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
32
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
33
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
34
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
35
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
36
Vatalanib Investigational Phase 2 212141-54-3 151194
37 Soblidotin Investigational Phase 2 149606-27-9
38 Exatecan Investigational Phase 2 171335-80-1
39
Camptothecin Experimental Phase 2 7689-03-4
40 Antibodies, Monoclonal Phase 2
41 Immunoglobulins Phase 2
42 Angiogenesis Inhibitors Phase 2
43 Angiogenesis Modulating Agents Phase 2
44 Antibodies Phase 2
45 Protein Kinase Inhibitors Phase 2,Phase 1
46 Vitamin B3 Phase 2
47 Micronutrients Phase 2
48 Nicotinic Acids Phase 2
49 Vitamins Phase 2
50 Trace Elements Phase 2

Interventional clinical trials:

(show all 26)
# Name Status NCT ID Phase Drugs
1 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
2 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
3 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
4 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
5 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
6 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
7 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Active, not recruiting NCT00423618 Phase 3
8 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
9 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
10 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
11 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2 romidepsin
12 Vatalanib in Treating Patients With Recurrent or Progressive Meningioma Completed NCT00348790 Phase 2 vatalanib
13 S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas Completed NCT00217620 Phase 2 sorafenib
14 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
15 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
16 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
17 Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00064220 Phase 2 soblidotin
18 Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2 perifosine
19 Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00041249 Phase 2 brostallicin
20 Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00041236 Phase 2 exatecan mesylate
21 Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors Completed NCT00025441 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
22 S9624 Ifosfamide in Treating Patients With Meningeal Tumors Terminated NCT00003292 Phase 2 ifosfamide
23 Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Stage IB, Stage II, or Stage III Soft Tissue Sarcoma Terminated NCT00740597 Phase 2
24 Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery Completed NCT00450736 Phase 1 celecoxib
25 Liposomal Doxorubicin Plus Ifosfamide in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00030784 Phase 1 ifosfamide;pegylated liposomal doxorubicin hydrochloride
26 Tissue Sample Collection From Patients With Soft Tissue Sarcoma of the Arms, Hands, Legs, or Feet Treated on Clinial Trial CRUK-VORTEX Unknown status NCT00900211

Search NIH Clinical Center for Hemangiopericytoma, Malignant

Cochrane evidence based reviews: hemangiopericytoma

Genetic Tests for Hemangiopericytoma, Malignant

Anatomical Context for Hemangiopericytoma, Malignant

MalaCards organs/tissues related to Hemangiopericytoma, Malignant:

41
Liver, Kidney, Brain, Bone, Lung, Thyroid, Spinal Cord

Publications for Hemangiopericytoma, Malignant

Articles related to Hemangiopericytoma, Malignant:

(show top 50) (show all 1121)
# Title Authors Year
1
Late Onset of Non-islet Cell Tumor Hypoglycemia Managed via Multidisciplinary Treatment in a Patient with a Solitary Fibrous Tumor. ( 29526941 )
2018
2
Tumor-to-tumor metastasis of lung adenocarcinoma into a spinal intradural solitary fibrous tumor: a case report. ( 30315364 )
2018
3
Synchronous Pulmonary Adenofibroma and Solitary Fibrous Tumor: Case Report and Review of the Literature. ( 30360665 )
2018
4
Preoperative Prediction of Solitary Fibrous Tumor/Hemangiopericytoma and Angiomatous Meningioma Using Magnetic Resonance Imaging Texture Analysis. ( 30240864 )
2018
5
Metastatic craniocervical hemangiopericytoma presenting with hydrocephalus and papilledema - Case review. ( 30318074 )
2018
6
Overexpression of IGF2 and IGF2 receptor in malignant solitary fibrous tumor with hypoglycemia: a case report. ( 30168002 )
2018
7
Metastatic Solitary Fibrous Tumor With Doege-Potter Syndrome: Hypoglycemia Treated by 90Y Radioembolization. ( 29293132 )
2018
8
Subcutaneous glucagon infusion and continuous glucose monitoring enable effective management of hypoglycemia in a patient with IGF-2-producing hemangiopericytoma. ( 29340167 )
2018
9
Very rare localization of a retroperitoneal hemangiopericytoma revealed by lumbosciatalgia: A case report. ( 30391737 )
2018
10
Solitary Fibrous Tumor of the Tongue: An Uncommon Cause of Obstructive Sleep Apnea. ( 30344384 )
2018
11
Diffusion weighted imaging may help differentiate intracranial hemangiopericytoma from meningioma. ( 30500359 )
2018
12
Preoperative Assessment of Pathologic Subtypes of Meningioma and Solitary Fibrous Tumor/Hemangiopericytoma Using Dynamic Computed Tomography: A Clinical Research Study. ( 29709742 )
2018
13
Value of SSTR2A and Claudin - 1 in Differentiating Meningioma from Schwannoma and Hemangiopericytoma. ( 29531582 )
2018
14
A broad ligament solitary fibrous tumor with Doege-Potter syndrome. ( 30278559 )
2018
15
Malignant Solitary Fibrous Tumor Metastatic to Widely Invasive Hurthle Cell Thyroid Carcinoma: A Distinct Tumor-to-Tumor Metastasis. ( 29616597 )
2018
16
Infantile hemangiopericytoma of the tongue-Efficacy of ex utero intrapartum treatment procedure and combined-modality therapy. ( 28365065 )
2018
17
Recurrent primary osseous hemangiopericytoma in the thoracic spine: a case report and literature review. ( 28993889 )
2018
18
Surgical management of spinal solitary fibrous tumor/hemangiopericytoma: a case series of 20 patients. ( 29127512 )
2018
19
Infantile hemangiopericytoma leading to hypovolemic shock in a neonate. ( 29314578 )
2018
20
Efficacy of adjuvant radiotherapy in the intracranial hemangiopericytoma. ( 29327171 )
2018
21
Intraoperative Transpedicular Onyx Injection to Reduce Vascularity of a Thoracic Hemangiopericytoma After Unsuccessful Preoperative Endovascular Embolization: a Technical Report. ( 29351687 )
2018
22
Clinical outcomes of intracranial solitary fibrous tumor and hemangiopericytoma: analysis according to the 2016 WHO classification of central nervous system tumors. ( 29372881 )
2018
23
Patterns of care and outcomes of postoperative radiation for intracranial hemangiopericytoma in United States hospitals. ( 29425741 )
2018
24
Solitary-fibrous tumor/hemangiopericytoma of the central nervous system: a population-based study. ( 29427152 )
2018
25
"Cor Occidere": a novel strategy of targeting the tumor core by radiosurgery in a radio- and chemo-resistant intracranial hemangiopericytoma. ( 29486569 )
2018
26
Solitary fibrous tumor/hemangiopericytoma: treatment results based on the 2016 WHO classification. ( 29521591 )
2018
27
Surveillance for metastatic hemangiopericytoma-solitary fibrous tumors-systematic literature review on incidence, predictors and diagnosis of extra-cranial disease. ( 29551003 )
2018
28
Prenatal vaginal congenital hemangiopericytoma (HPC): a rare vaginal tumor of the fetus. ( 29573489 )
2018
29
Association between programmed cell death ligand-1 expression and extracranial metastasis in intracranial solitary fibrous tumor/hemangiopericytoma. ( 29675794 )
2018
30
Liquid Biopsy in Rare Cancers: Lessons from Hemangiopericytoma. ( 29707475 )
2018
31
Atypical epidural hemangiopericytoma presenting with visual disturbance. ( 29721348 )
2018
32
β-catenin (CTNNB1) mutation and LEF1 expression in sinonasal glomangiopericytoma (sinonasal-type hemangiopericytoma). ( 29736797 )
2018
33
Unusual occurrence of orbital hemangiopericytoma in the zygomatic bone of an adolescent: a case report. ( 29785407 )
2018
34
Malignant Hemangiopericytoma of the Liver Masquerading as Hepatocellular Carcinoma. ( 29887712 )
2018
35
Hemangiopericytoma/Solitary Fibrous Tumor of the Buccal Mucosa. ( 29963445 )
2018
36
Unusual Case of Metastatic Intracranial Hemangiopericytoma and Emphasis on Role of 68Ga-PSMA PET in Imaging. ( 30036256 )
2018
37
The radiation therapy options of intracranial hemangiopericytoma: An overview and update on a rare vascular mesenchymal tumor. ( 30101003 )
2018
38
A novel mouse model of hemangiopericytoma due to loss of Tsc2. ( 30124871 )
2018
39
Diagnosis and treatment of solitary fibrous tumor/hemangiopericytoma of central nervous system. Retrospective report of 17 patients and literature review. ( 30183202 )
2018
40
Pathological prognostic markers in central nervous system solitary fibrous tumour/hemangiopericytoma: Evidence from a small series. ( 30183767 )
2018
41
Renal solitary fibrous tumor/hemangiopericytoma: computed tomography findings and clinicopathologic features. ( 30225611 )
2018
42
Canine spindle cell tumor mimicking human classical hemangiopericytoma. ( 30232316 )
2018
43
Meningeal solitary fibrous tumor/hemangiopericytoma: Emphasizing on STAT 6 immunohistochemistry with a review of literature. ( 30233017 )
2018
44
Primary epidural hemangiopericytoma of the thoracic spine: Case report and literature review. ( 30352760 )
2018
45
Pathological Features and Clinical Course in Patients With Recurrent or Malignant Orbital Solitary Fibrous Tumor/Hemangiopericytoma. ( 30371551 )
2018
46
A Case Report of Meningeal Hemangiopericytoma: A nine-year journey from the brain to the spine. ( 30447454 )
2018
47
Giant bilateral renal metastases from a meningeal hemangiopericytoma. ( 30488871 )
2018
48
Solitary fibrous tumor/hemangiopericytoma of the optic canal. ( 30499771 )
2018
49
Intraspinal Dissemination and Local Recurrence of an Intracranial Hemangiopericytoma: Case Report. ( 30503286 )
2018
50
Solitary fibrous tumor/hemangiopericytoma of spinal cord: a retrospective single-center study of 16 cases. ( 30554000 )
2018

Variations for Hemangiopericytoma, Malignant

Cosmic variations for Hemangiopericytoma, Malignant:

9 (show all 15)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM584 NRAS soft tissue,blood vessel,haemangioma,capillary c.182A>G p.Q61R 1:114713908-114713908 6
2 COSM580 NRAS soft tissue,blood vessel,haemangioma,capillary c.181C>A p.Q61K 1:114713909-114713909 6
3 COSM529 KRAS soft tissue,blood vessel,haemangioma,capillary c.37G>C p.G13R 12:25245348-25245348 6
4 COSM521 KRAS soft tissue,blood vessel,haemangioma,capillary c.35G>A p.G12D 12:25245350-25245350 6
5 COSM516 KRAS soft tissue,blood vessel,haemangioma,capillary c.34G>T p.G12C 12:25245351-25245351 6
6 COSM487 HRAS soft tissue,blood vessel,haemangioma,capillary c.37G>A p.G13S 11:534286-534286 6
7 COSM6503574 HRAS soft tissue,blood vessel,haemangioma,capillary c.145G>A p.E49K 11:533911-533911 6
8 COSM486 HRAS soft tissue,blood vessel,haemangioma,capillary c.37G>C p.G13R 11:534286-534286 6
9 COSM6503575 HRAS soft tissue,blood vessel,haemangioma,capillary c.44G>A p.G15D 11:534279-534279 6
10 COSM499 HRAS soft tissue,blood vessel,haemangioma,capillary c.182A>G p.Q61R 11:533874-533874 6
11 COSM6503576 HRAS soft tissue,blood vessel,haemangioma,capillary c.100C>T p.P34S 11:534223-534223 6
12 COSM52975 GNAQ soft tissue,blood vessel,haemangioma,capillary c.548G>A p.R183Q 9:77797577-77797577 6
13 COSM21651 GNA11 soft tissue,blood vessel,haemangioma,capillary c.547C>T p.R183C 19:3115014-3115014 6
14 COSM476 BRAF soft tissue,blood vessel,haemangioma,capillary c.1799T>A p.V600E 7:140753336-140753336 6
15 COSM449 BRAF soft tissue,blood vessel,haemangioma,capillary c.1391G>A p.G464E 7:140781617-140781617 6

Expression for Hemangiopericytoma, Malignant

Search GEO for disease gene expression data for Hemangiopericytoma, Malignant.

Pathways for Hemangiopericytoma, Malignant

Pathways related to Hemangiopericytoma, Malignant according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.33 DES FGF23 IGF2 MDM2 MUC1 NGFR
2 11.95 ACTC1 DES MUC1 VIM
3 10.99 ACTC1 DES VIM
4 10.98 F13A1 MUC1 STAT6 VIM

GO Terms for Hemangiopericytoma, Malignant

Cellular components related to Hemangiopericytoma, Malignant according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.5 F13A1 FGF23 HBA1 IGF2 MUC1 NGFR
2 blood microparticle GO:0072562 8.8 ACTC1 F13A1 HBA1

Biological processes related to Hemangiopericytoma, Malignant according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.46 F13A1 MUC1 STAT6 VIM
2 intermediate filament organization GO:0045109 9.32 DES VIM
3 response to magnesium ion GO:0032026 9.26 FGF23 MDM2
4 negative regulation of neuron projection development GO:0010977 9.13 MDM2 NGFR VIM
5 muscle filament sliding GO:0030049 8.8 ACTC1 DES VIM

Molecular functions related to Hemangiopericytoma, Malignant according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.17 DES HACL1 MDM2 NAB2 S100B STAT6

Sources for Hemangiopericytoma, Malignant

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....